ReviewThe American journal of tropical medicine and hygiene2019
Falsified and Substandard Drugs: Stopping the Pandemic.
Review in The American journal of tropical medicine and hygiene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Health, Economic, and Social Impacts of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review of Methodological Approaches.The American journal of tropical medicine and hygiene · 2023Pooled it
- Quality of medicines for life-threatening pregnancy complications in low- and middle-income countries: A systematic review.PloS one · 2020Pooled it
- Tiered manufacturing of pharmaceuticals as a commercial determinant of health: Implications for medicine quality and equity.PLOS global public health · 2026Article
- Visual assessment of antimicrobial medicine packaging and labeling quality in pharmacies of Ho Municipality, Ghana.PloS one · 2026Article
- Quality evaluation of cephalexin, cefuroxime, and ceftriaxone medicines marketed in Addis Ababa city, Ethiopia with three tier level approach and anti-microbial assays.BMC pharmacology & toxicology · 2025Article
- Healthcare workers´ perspectives on antibiotic utilization in children under five years of age in the Eastern Democratic Republic of the Congo.Antimicrobial resistance and infection control · 2025Article
- Knowledge, attitudes and practices on substandard and falsified medicines for human and animal use in Wakiso district, Uganda.Journal of pharmaceutical policy and practice · 2025Article
- Use of Blockchain Technology to Accelerate Digital Health Transformation Programs.Blockchain in healthcare today · 2025Review
- Suspected poor-quality medicines in Kenya: a retrospective descriptive study of medicine quality-related complaints reports in Kenya's pharmacovigilance database.BMC public health · 2024Article
- The role of constraints and information gaps in driving risky medicine purchasing practices in four African countries.Health policy and planning · 2024Article
- Identifying and costing common gaps in Central and West Africa pharmaceutical regulation.Frontiers in medicine · 2024Article
- Investigating the Presence of Falsified and Poor-Quality Fixed-Dose Combination Artemether-Lumefantrine Pharmaceutical Dosage Forms in Kumasi, Ghana.Advances in pharmacological and pharmaceutical sciences · 2024Article
- The response to substandard and falsified medical products in francophone sub-Saharan African countries: weaknesses and opportunities.Journal of pharmaceutical policy and practice · 2023Article
- Sub-standard or Sub-legal? Distribution, Pharma Dossiers, and Fake-talk in India.Medicine anthropology theory · 2023Article
- A comprehensive framework identifying barriers to global health R&D innovation and access.BMJ global health · 2023Review
- Ensuring vaccine safety: Case studies of falsified influenza vaccines detected in Brazil.Vaccine: X · 2023Article
- Post-market quality assessment of 22 ciprofloxacin brands by HPLC available in Bangladesh market.Heliyon · 2023Article
- Insights from a qualitative study of the procurement and manufacture of active pharmaceutical ingredients in India.BMJ global health · 2023Review
- Substandard and Falsified Medications: A Barrier to Global Health Equity Exemplified in Ecuador.Neurocritical care · 2023Article
- Improved knowledge on substandard and falsified (SF) medical products through a dedicated course for pharmacy students at three universities in sub-Saharan Africa.BMJ global health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Falsified and substandard medicines are associated with tens of thousands of deaths, mainly in young children in poor countries. Poor-quality drugs exact an annual economic toll of up to US$200 billion and contribute to the increasing peril of antimicrobial resistance. The WHO has emerged recently as the global leader in the battle against poor-quality drugs, and pharmaceutical companies have increased their roles in assuring the integrity of drug supply chains. Despite advances in drug quality surveillance and detection technology, more efforts are urgently required in research, policy, and field monitoring to halt the pandemic of bad drugs. In addition to strengthening international and national pharmaceutical governance, in part by national implementation of the Model Law on Medicines and Crime, a quantifiable Sustainable Development Goal target and an international convention to insure drug quality and safety are urgent priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.